161 related articles for article (PubMed ID: 28724330)
1. Immunotherapy advances for mesothelioma treatment.
Bakker E; Guazzelli A; Ashtiani F; Demonacos C; Krstic-Demonacos M; Mutti L
Expert Rev Anticancer Ther; 2017 Sep; 17(9):799-814. PubMed ID: 28724330
[TBL] [Abstract][Full Text] [Related]
2. Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma.
Guazzelli A; Bakker E; Tian K; Demonacos C; Krstic-Demonacos M; Mutti L
Expert Opin Investig Drugs; 2017 Aug; 26(8):933-944. PubMed ID: 28679291
[TBL] [Abstract][Full Text] [Related]
3. [Immunotherapy and malignant mesothelioma: clinical perspectives].
Grégoire M; Ebstein F
Bull Cancer; 2007 Jan; 94(1):23-31. PubMed ID: 17237002
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy-based treatment strategies for malignant mesothelioma.
Schwarzenberger P; Byrne P; Kolls JK
Curr Opin Mol Ther; 1999 Feb; 1(1):104-11. PubMed ID: 11249674
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cell-based immunotherapy in mesothelioma.
Cornelissen R; Lievense LA; Heuvers ME; Maat AP; Hendriks RW; Hoogsteden HC; Hegmans JP; Aerts JG
Immunotherapy; 2012 Oct; 4(10):1011-22. PubMed ID: 23148753
[TBL] [Abstract][Full Text] [Related]
6. Immunological effects of chemotherapy and radiotherapy against brain tumors.
Weiss T; Weller M; Roth P
Expert Rev Anticancer Ther; 2016 Oct; 16(10):1087-94. PubMed ID: 27598516
[TBL] [Abstract][Full Text] [Related]
7. Novel and Future Treatment Options in Mesothelioma: A Systematic Review.
Štrbac D; Dolžan V
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216091
[TBL] [Abstract][Full Text] [Related]
8. Immunity and malignant mesothelioma: from mesothelial cell damage to tumor development and immune response-based therapies.
Izzi V; Masuelli L; Tresoldi I; Foti C; Modesti A; Bei R
Cancer Lett; 2012 Sep; 322(1):18-34. PubMed ID: 22394996
[TBL] [Abstract][Full Text] [Related]
9. New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors.
Ciccarese C; Alfieri S; Santoni M; Santini D; Brunelli M; Bergamini C; Licitra L; Montironi R; Tortora G; Massari F
Expert Opin Drug Metab Toxicol; 2016; 12(1):57-75. PubMed ID: 26565919
[TBL] [Abstract][Full Text] [Related]
10. Malignant pleural mesothelioma--an update.
Stewart DJ; Edwards JG; Smythe WR; Waller DA; O'Byrne KJ
Int J Occup Environ Health; 2004; 10(1):26-39. PubMed ID: 15070023
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant and intrapleural therapies for malignant pleural mesothelioma.
Tsao AS; Mehran R; Roth JA
Clin Lung Cancer; 2009 Jan; 10(1):36-41. PubMed ID: 19289370
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy strategies for mesothelioma - the role of tumor specific neoantigens in a new era of precision medicine.
Ye L; Ma S; Robinson BW; Creaney J
Expert Rev Respir Med; 2019 Feb; 13(2):181-192. PubMed ID: 30596292
[TBL] [Abstract][Full Text] [Related]
13. Biological basis for novel mesothelioma therapies.
Obacz J; Yung H; Shamseddin M; Linnane E; Liu X; Azad AA; Rassl DM; Fairen-Jimenez D; Rintoul RC; Nikolić MZ; Marciniak SJ
Br J Cancer; 2021 Oct; 125(8):1039-1055. PubMed ID: 34226685
[TBL] [Abstract][Full Text] [Related]
14. Tumor-associated macrophages in thoracic malignancies.
Lievense LA; Bezemer K; Aerts JG; Hegmans JP
Lung Cancer; 2013 Jun; 80(3):256-62. PubMed ID: 23489559
[TBL] [Abstract][Full Text] [Related]
15. Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists.
Beatty GL; Li Y; Long KB
Expert Rev Anticancer Ther; 2017 Feb; 17(2):175-186. PubMed ID: 27927088
[TBL] [Abstract][Full Text] [Related]
16. New roads open up for implementing immunotherapy in mesothelioma.
Cornelissen R; Heuvers ME; Maat AP; Hendriks RW; Hoogsteden HC; Aerts JG; Hegmans JP
Clin Dev Immunol; 2012; 2012():927240. PubMed ID: 22778767
[TBL] [Abstract][Full Text] [Related]
17. Developing immunotherapeutic strategies to target brain tumors.
Lieberman NA; Moyes KW; Crane CA
Expert Rev Anticancer Ther; 2016 Jul; 16(7):775-88. PubMed ID: 27253692
[TBL] [Abstract][Full Text] [Related]
18. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma.
Hegmans JP; Veltman JD; Lambers ME; de Vries IJ; Figdor CG; Hendriks RW; Hoogsteden HC; Lambrecht BN; Aerts JG
Am J Respir Crit Care Med; 2010 Jun; 181(12):1383-90. PubMed ID: 20167848
[TBL] [Abstract][Full Text] [Related]
19. Novel Insights Into Mesothelioma Therapy: Emerging Avenues and Future Prospects.
Kuryk L; Rodella G; Staniszewska M; Pancer KW; Wieczorek M; Salmaso S; Caliceti P; Garofalo M
Front Oncol; 2022; 12():916839. PubMed ID: 35785199
[TBL] [Abstract][Full Text] [Related]
20. Novel intrapleural therapies for malignant diseases.
Haas AR; Sterman DH
Respiration; 2012; 83(4):277-92. PubMed ID: 22456231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
